Clinical Trials Directory

Trials / Completed

CompletedNCT04680780

Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
63 (actual)
Sponsor
University of Cologne · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time. Recently published data show that the beneficial effect is not due to caloric restriction per se but due to the induction of the state of ketosis. Dietary interventions leading to ketosis profoundly inhibited renal cyst growth in rodent models of PKD. In addition, acute fasting led to rapid regression of renal cystic burden in mouse, rat and feline models of PKD. Due to these compelling effects in a multitude of PKD animal models, and due to the fact that well-established dietary interventions have a tremendous translational potential, KETO-ADPKD will test such interventions regimens in ADPKD patients. Two well-established ketogenic dietary regimens will be tested in comparison to a control group to address the following four questions: 1. Feasibility: Are ketogenic dietary interventions acceptable to ADPKD patients in everyday life? 2. Safety: Are there adverse events of ketogenic dietary interventions in ADPKD patients? 3. Efficacy: Do the dietary interventions reach the metabolic endpoints? Do they have a short-term impact on kidney volume? 4. Which of the two diets is the optimal approach? These questions will be addressed in an exploratory, randomized, open, single center, three-arm dietary intervention study using the following interventions in 21 ADPKD patients per treatment arm: A) Ketogenic diet B) 3-day water fasting C) Control: ad libitum food intake (no diet)

Conditions

Interventions

TypeNameDescription
OTHERKetogenic dietPatients will follow a classical ketogenic diet for 3 months
OTHER3-days water-fastingPatients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
OTHERControlPatients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.

Timeline

Start date
2021-01-10
Primary completion
2022-08-12
Completion
2022-08-12
First posted
2020-12-23
Last updated
2022-08-24

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04680780. Inclusion in this directory is not an endorsement.